Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458794 | 0.82 | KDM4E (0.43) | SMN1; SMN2ALDH1A1POLBHPGDNPC1 | |
| SCHEMBL1436801 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1POLBADORA3NPSR1 | |
| SCHEMBL7229102 | 0.80 | APP (0.42) | SMN1; SMN2ALDH1A1ALOX5NPSR1GAA | |
| SCHEMBL2088949 | 0.77 | PDPK1 (0.38) | SMN1; SMN2ALDH1A1POLBADORA3ADORA2A | |
| SCHEMBL15287127 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1POLBHPGDNPC1 | |
| SCHEMBL7220760 | 0.71 | KDM4E (0.44) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL2103587 | 0.69 | HPGD (0.54) | SMN1; SMN2ALDH1A1NPSR1HPGDNPC1 | |
| SCHEMBL11904904 | 0.68 | CYP1A2 (0.47) | SMN1; SMN2ALDH1A1POLBNPSR1HPGD | |
| SCHEMBL11904982 | 0.68 | CYP1A2 (0.47) | SMN1; SMN2ALDH1A1POLBNPSR1HPGD | |
| SCHEMBL1671383 | 0.67 | ALOX5 (0.40) | SMN1; SMN2ALDH1A1POLBALOX5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | claimed |
| US-8648206-B2 | Light-activated actuator element | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102712634-A | Heteroarylpiperidine and -piperazine derivatives | BAYER CROPSCIENCE AG | 2012-10-03 | — | — | CN | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | SMN1; SMN2 2800/4885ALDH1A1 1801/4885POLB 4868/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | SMN1; SMN2 2529/4885ALDH1A1 233/4885POLB 3835/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | SMN1; SMN2 1935/4885ALDH1A1 133/4885POLB 4075/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | SMN1; SMN2 2529/4885ALDH1A1 233/4885POLB 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.